GO
Loading...

Finerman's Fine Print: Roche Hostility

Wednesday, 25 Jan 2012 | 5:18 PM ET

Fast Money trader Karen Finerman explains what's behind Roche's tender offer for Illumina; and the best way to play the biotech takeout trend.